CClinicalTrials.gg
CompletedNCT04790201VITALUpdated Aug 13, 2024Results posted

Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam

An interventional study of Friendship Bench Delivered by Professional Counselor and Friendship Bench Delivered by Lay Counselor in HIV Infections, Behavioral Symptoms and Depression, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This project will adapt and pilot a feasible and effective problem-solving therapy designed for low-resource settings to address common mental disorders like depression and anxiety - the Friendship Bench- in a Vietnamese population of individuals living with HIV who also have opiate use disorder. The Friendship Bench approach has the potential to make an important contribution to address CMDs and reduce barriers to HIV treatment success among people living with HIV (PLWH) with Opioid Use Disorder (OUD), a critical population driving the HIV epidemic in Vietnam and many Southeast Asian countries. This proposal will generate critical evidence for designing a fully powered clinical trial to test the investigation team's adapted FB protocol in improving HIV, mental health, and drug use treatment outcomes for this vulnerable population.

Read the detailed description

Injection drug use is the primary driver of the HIV epidemic in Southeast Asia. In 2017, the HIV prevalence among people who inject drugs (PWID) in Southeast Asia was 15%. PWID, most of whom have OUD, who are living with HIV have low rates of retention in care, antiretroviral therapy (ART) initiation, and viral suppression. PWID also experience high rates of HIV-related and all-cause mortality. Common mental disorders (CMDs), including depressive, anxiety, and stress-related illnesses, occur in 40-50% of PLWH and OUD. Despite serious consequences of mental illness on health and HIV progression, mental illness remains under-diagnosed and under-treated in HIV populations, especially in low- and middle-income countries (LMICs), such as many countries in Southeast Asia.

To respond to the great need for mental health treatment in low- and middle-income countries, the global mental health field has focused on developing task-shifting and integration approaches that equip non-specialists to deliver evidence-based mental health interventions at scale. However, such task shifting interventions to address CMDs have received limited attention in Southeast Asia among OUD. Vietnam, with its high prevalence of PLWH and OUD, its integration of methadone maintenance therapy (MMT) with HIV care, and its priority for developing CMD care for this population, is an ideal setting to evaluate task-shifting mental health approaches to address CMDs and improve HIV care outcomes.

The Friendship Bench (FB) is a feasible and effective task-shifting mental health intervention designed for low-resource settings that is a strong candidate to address CMDs in this population. FB is a problem solving therapy-based intervention with demonstrated effectiveness in treating CMDs among primary care patients when delivered by lay counselors. Lay counselors may effectively deliver FB to PLWH with OUD, but CMD may prove more difficult to treat in patients with OUD and require professionally trained counselors to be effective.

The investigators' objective is to complete a pilot randomized trial of 75 patients from 4 MMT clinics in Hanoi. The investigators' specific aims are: 1) To adapt the Friendship Bench (FB) protocol to be optimized for PLWH and OUD in Vietnam; and 2) To evaluate the feasibility, fidelity, and acceptability of the adapted FB as well as preliminary indicators of its impact in improving CMDs and HIV care and drug use treatment outcomes. The Friendship Bench approach has the potential to make an important contribution to address CMDs and reduce barriers to HIV treatment success among PLWH with OUD, a critical population driving the HIV epidemic in Vietnam and many Southeast Asian countries. This proposal will generate critical evidence for designing a fully powered clinical trial to test the adapted FB protocol in improving HIV, mental health, and drug use treatment outcomes for this vulnerable population.

02

Conditions studied

  • HIV Infections
  • Behavioral Symptoms
  • Depression
  • Anxiety
  • Opioid-use Disorder
  • Virus Infection
  • Immune System Diseases
  • Opioid Dependence
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Eligible individuals will meet the following criteria:

  • Adult patients (18 years and older) being treated at the Methadone Maintenance Treatment (MMT) clinic
  • Medical record indicates infection with HIV
  • Have been screened with the Depression Anxiety Stress Scale-21 (DASS-21) which has been translated, standardized and validated in the Vietnamese population with a positive result indicating a CMD. The investigators will consider as eligible all patients with a depression subscale score ≥ 7, an anxiety subscale score ≥ 6, and/or a stress subscale score ≥ 10. Elevated depressive symptoms be present for ≥2 weeks and elevated anxiety or post-traumatic stress-related symptoms be present for ≥1 month. The investigators will consider a positive screen for any of the three categories as indicating a CMD.

Exclusion criteria

Exclusion Criteria:

  • Those with evidence of psychosis or bipolar disorder per the Mini International Neuropsychiatric Interview (MINI) will be excluded.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Friendship Bench Delivered by Professional Counselor

    Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a professional counselor. Individuals enrolled in this arm will receive 6 weekly counseling sessions per the adapted FB protocol (Aim 1).

    Behavioral: Friendship Bench Delivered by Professional Counselor

  • Experimental
    Friendship Bench Delivered by Lay Counselor

    Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Individuals enrolled in this arm will initiate FB with a trained lay counselor. Individuals enrolled in this arm arm will receive 6 weekly counselling sessions per the adapted FB protocol (Aim 1).

    Behavioral: Friendship Bench Delivered by Lay Counselor

  • Active comparator
    Enhanced Usual Care

    Participants seeking HIV and/or MMT services at participating clinics in Hanoi, Vietnam will be enrolled in this study arm during study recruitment. Enhanced usual care will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care.

    Behavioral: Enhanced Usual Care

Interventions

  • BehavioralFriendship Bench Delivered by Professional Counselor

    Participants randomized to this arm will receive the Friendship Bench protocol delivered by a professional counselor.

  • BehavioralFriendship Bench Delivered by Lay Counselor

    Participants randomized to this arm will receive the Friendship Bench protocol delivered by a trained lay counselor.

  • BehavioralEnhanced Usual Care

    Enhanced usual care (EUC) will include general training of the HIV providers and clinics about CMD identification and management, and feedback to the HIV provider of the status of their enrolled patient to allow follow-up per the clinic's standard care. Information will be collected in follow-up interviews to characterize the care that patients receive. These activities will occur in all three arms, but they are the only activities in the EUC arm.

05

What researchers measure

Primary outcomes

  1. Total Number of Participants Who Were Eligible and Enrolled (Intervention Feasibility)

    This measure of feasibility will be measured as the ability to successfully enroll people living with HIV (PLWH) and opioid use disorder (OUD) with CMDs in the pilot intervention. Feasibility will be evaluated by measuring the recruitment rate (number of patients approached in order to accrue the final sample).

    Time frame: Baseline

  2. Study Retention (Study Feasibility)

    This measure of feasibility will be measured as the ability to retain PLWH and OUD with CMDs in the pilot trial. Feasibility will be evaluated by measuring the number of participants retained in the study (number of patients enrolled at baseline who are still enrolled in the trial), through study completion.

    Time frame: Through study completion, an average of 12 months

  3. Percent of FB Sessions Attended (Intervention Feasibility)

    The percent of FB sessions attended by participants out of total FB sessions offered, during the target intervention duration of 6 weeks.

    Time frame: 6 weeks

  4. Number of Participants Satisfied With Friendship Bench (Intervention Acceptability)

    The number of patients who were either very satisfied or somewhat satisfied with the FB among all participants who received the FB. Satisfaction will be measured using a single question with a 4-point Likert scale-- 1 indicates high satisfaction and 4 indicates high dissatisfaction.

    Time frame: 6 weeks

  5. Number of Counseling Sessions Meeting Fidelity Threshold (Intervention Fidelity)

    The total number of FB sessions meeting or exceeding for at least 75% of the total number of fidelity checklist items assessed per session.

    Time frame: 6 weeks

Secondary outcomes

  1. Number of Participants Achieving HIV Viral Suppression

    HIV viral load will be measured from clinical records, or measured and ordered by the study if no viral load is collected in the appropriate window. Viral suppression is defined as \<20 copies of HIV-1 RNA per milliliter.

    Time frame: 6 months after enrollment

  2. Proportion of Scheduled HIV Visits That Were Attended in the 12-Month Follow-Up Period

    The proportion of scheduled visits in the 12-month follow-up period that are attended vs. no-shows (the "kept visit proportion"), with no-show defined as no appointment kept in the 30 days following a scheduled appointment. HIV appointment data will be abstracted from clinic records at the end of the study period.

    Time frame: Study baseline through 12 months of follow-up

  3. Total CMD Symptoms Score for Participants

    CMD symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. The total scale is calculated by summing the subscales, range 0-126, for depression (threshold ≥14), anxiety (threshold ≥10), and stress (threshold ≥19); higher scores indicate higher severity of symptoms.

    Time frame: 6 weeks after enrollment

  4. Change in CMD Symptoms

    The change in CMD symptoms from baseline to 6 weeks in the DASS-21 total score is calculated as Baseline DASS-21 total score minus the Week 6 DASS-21 total score. CMD symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. The total scale is calculated by summing the subscales, range 0-126, for depression (threshold ≥14), anxiety (threshold ≥10), and stress (threshold ≥19); higher scores indicate higher severity of symptoms.

    Time frame: Baseline, 6 weeks after enrollment

  5. Mean Depressive Disorder Score Among Participants

    Depression symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the depression subscale range from 0-42, with ≥ 14 on the depression subscale indicating a depressive disorder.

    Time frame: 6 weeks after enrollment

  6. Absolute Reduction in Depressive Symptoms

    The absolute reduction of depressive symptoms from baseline to 6 weeks will be evaluated via the DASS-21 depression subscale. Depression symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the depression subscale range from 0-42, with ≥ 14 on the depression subscale indicating a depressive disorder.

    Time frame: 6 weeks after enrollment

  7. Mean Anxiety Disorder Score Among Participants

    Anxiety symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the anxiety subscale range from 0-42, with ≥ 10 on the anxiety subscale indicating an anxiety disorder.

    Time frame: 6 weeks after enrollment

  8. Absolute Reduction in Anxiety Symptoms

    The absolute reduction of anxiety symptoms from baseline to 6 weeks will be evaluated via the DASS-21 anxiety subscale. Anxiety symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the anxiety subscale range from 0-42, with ≥ 10 on the anxiety subscale indicating an anxiety disorder.

    Time frame: 6 weeks after enrollment

  9. Mean Stress Disorder Score Among Participants

    Stress symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the stress subscale range from 0-42, with ≥ 19 on the stress subscale indicating a stress disorder.

    Time frame: 6 weeks after enrollment

  10. Absolute Reduction in Stress Symptoms

    The absolute reduction of stress symptoms from baseline to 6 weeks will be evaluated via the DASS-21 stress scale. Stress symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the stress subscale range from 0-42, with ≥ 19 on the stress subscale indicating a stress disorder.

    Time frame: 6 weeks after enrollment

  11. Mean Proportion of Days With MMT Adherence

    Out of the first 183 days of study participation, the total number of days a participant attended their MMT visit appointment divided by 183 days.

    Time frame: Study baseline through 6 months of follow-up

06

Results

Posted Aug 13, 2024

Participant flow

Study recruitment began in February 2022. Recruitment occurred in Methadone Maintenance Treatment (MMT) clinics located in Hanoi, Vietnam.

Participant flow — Overall Study
MilestoneFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Started262526
Completed252423
Not completed113
Withdrew: Lost to follow-up002
Withdrew: Death010
Withdrew: Protocol violation101

Outcome measures

PrimaryTotal Number of Participants Who Were Eligible and Enrolled (Intervention Feasibility)

This measure of feasibility will be measured as the ability to successfully enroll people living with HIV (PLWH) and opioid use disorder (OUD) with CMDs in the pilot intervention. Feasibility will be evaluated by measuring the recruitment rate (number of patients approached in order to accrue the final sample).

Time frame:
Baseline
Reported as:
Count of participants · Participants
Total Number of Participants Who Were Eligible and Enrolled (Intervention Feasibility)
ParticipantsStudy Population
Total Number of Participants Who Were Eligible and Enrolled (Intervention Feasibility)75
PrimaryStudy Retention (Study Feasibility)

This measure of feasibility will be measured as the ability to retain PLWH and OUD with CMDs in the pilot trial. Feasibility will be evaluated by measuring the number of participants retained in the study (number of patients enrolled at baseline who are still enrolled in the trial), through study completion.

Time frame:
Through study completion, an average of 12 months
Reported as:
Count of participants · Participants
Study Retention (Study Feasibility)
ParticipantsFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Study Retention (Study Feasibility)252523
PrimaryPercent of FB Sessions Attended (Intervention Feasibility)

The percent of FB sessions attended by participants out of total FB sessions offered, during the target intervention duration of 6 weeks.

Time frame:
6 weeks
Reported as:
Number · percent of FB Sessions Attended
Percent of FB Sessions Attended (Intervention Feasibility)
percent of FB Sessions AttendedFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Percent of FB Sessions Attended (Intervention Feasibility)100100—
PrimaryNumber of Participants Satisfied With Friendship Bench (Intervention Acceptability)

The number of patients who were either very satisfied or somewhat satisfied with the FB among all participants who received the FB. Satisfaction will be measured using a single question with a 4-point Likert scale-- 1 indicates high satisfaction and 4 indicates high dissatisfaction.

Time frame:
6 weeks
Reported as:
Count of participants · Participants
Number of Participants Satisfied With Friendship Bench (Intervention Acceptability)
ParticipantsFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Number of Participants Satisfied With Friendship Bench (Intervention Acceptability)2525—
PrimaryNumber of Counseling Sessions Meeting Fidelity Threshold (Intervention Fidelity)

The total number of FB sessions meeting or exceeding for at least 75% of the total number of fidelity checklist items assessed per session.

Time frame:
6 weeks
Reported as:
Number · Number of sessions meeting fidelity
Number of Counseling Sessions Meeting Fidelity Threshold (Intervention Fidelity)
Number of sessions meeting fidelityFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Number of Counseling Sessions Meeting Fidelity Threshold (Intervention Fidelity)6642—
SecondaryNumber of Participants Achieving HIV Viral Suppression

HIV viral load will be measured from clinical records, or measured and ordered by the study if no viral load is collected in the appropriate window. Viral suppression is defined as \<20 copies of HIV-1 RNA per milliliter.

Time frame:
6 months after enrollment
Reported as:
Count of participants · Participants
Number of Participants Achieving HIV Viral Suppression
ParticipantsFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Number of Participants Achieving HIV Viral Suppression192121
SecondaryProportion of Scheduled HIV Visits That Were Attended in the 12-Month Follow-Up Period

The proportion of scheduled visits in the 12-month follow-up period that are attended vs. no-shows (the "kept visit proportion"), with no-show defined as no appointment kept in the 30 days following a scheduled appointment. HIV appointment data will be abstracted from clinic records at the end of the study period.

Time frame:
Study baseline through 12 months of follow-up
Reported as:
Number · proportion of scheduled visits attended
Proportion of Scheduled HIV Visits That Were Attended in the 12-Month Follow-Up Period
proportion of scheduled visits attendedFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Proportion of Scheduled HIV Visits That Were Attended in the 12-Month Follow-Up Period0.950.940.92
SecondaryTotal CMD Symptoms Score for Participants

CMD symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. The total scale is calculated by summing the subscales, range 0-126, for depression (threshold ≥14), anxiety (threshold ≥10), and stress (threshold ≥19); higher scores indicate higher severity of symptoms.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Total CMD Symptoms Score for Participants
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Total CMD Symptoms Score for Participants27.28 ± 26.423.9 ± 21.432.3 ± 22.7
SecondaryChange in CMD Symptoms

The change in CMD symptoms from baseline to 6 weeks in the DASS-21 total score is calculated as Baseline DASS-21 total score minus the Week 6 DASS-21 total score. CMD symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. The total scale is calculated by summing the subscales, range 0-126, for depression (threshold ≥14), anxiety (threshold ≥10), and stress (threshold ≥19); higher scores indicate higher severity of symptoms.

Time frame:
Baseline, 6 weeks after enrollment
Reported as:
Mean · score on a scale
Change in CMD Symptoms
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Change in CMD Symptoms-24.2 ± 25.8-23.5 ± 30.2-13.4 ± 25.4
SecondaryMean Depressive Disorder Score Among Participants

Depression symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the depression subscale range from 0-42, with ≥ 14 on the depression subscale indicating a depressive disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Mean Depressive Disorder Score Among Participants
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Mean Depressive Disorder Score Among Participants8.2 ± 12.36.2 ± 7.49.0 ± 9.1
SecondaryAbsolute Reduction in Depressive Symptoms

The absolute reduction of depressive symptoms from baseline to 6 weeks will be evaluated via the DASS-21 depression subscale. Depression symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the depression subscale range from 0-42, with ≥ 14 on the depression subscale indicating a depressive disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Absolute Reduction in Depressive Symptoms
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Absolute Reduction in Depressive Symptoms-8.2 ± 10.6-7.8 ± 10.5-5.4 ± 10.7
SecondaryMean Anxiety Disorder Score Among Participants

Anxiety symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the anxiety subscale range from 0-42, with ≥ 10 on the anxiety subscale indicating an anxiety disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Mean Anxiety Disorder Score Among Participants
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Mean Anxiety Disorder Score Among Participants8.2 ± 8.38.3 ± 8.711.0 ± 7.9
SecondaryAbsolute Reduction in Anxiety Symptoms

The absolute reduction of anxiety symptoms from baseline to 6 weeks will be evaluated via the DASS-21 anxiety subscale. Anxiety symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the anxiety subscale range from 0-42, with ≥ 10 on the anxiety subscale indicating an anxiety disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Absolute Reduction in Anxiety Symptoms
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Absolute Reduction in Anxiety Symptoms-6.4 ± 6.7-5.9 ± 10.6-3.9 ± 9.4
SecondaryMean Stress Disorder Score Among Participants

Stress symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the stress subscale range from 0-42, with ≥ 19 on the stress subscale indicating a stress disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Mean Stress Disorder Score Among Participants
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Mean Stress Disorder Score Among Participants10.9 ± 9.89.4 ± 8.212.3 ± 7.8
SecondaryAbsolute Reduction in Stress Symptoms

The absolute reduction of stress symptoms from baseline to 6 weeks will be evaluated via the DASS-21 stress scale. Stress symptoms will be evaluated via the 21-item Depression, Anxiety, and Stress Scale (DASS-21), which consists of three subscales. Responses are ranked from 0 (Does not apply to me at all) to 3 (Applied to me very much or most of the time). All subscales are multiplied by 2. Scores on the stress subscale range from 0-42, with ≥ 19 on the stress subscale indicating a stress disorder.

Time frame:
6 weeks after enrollment
Reported as:
Mean · score on a scale
Absolute Reduction in Stress Symptoms
score on a scaleFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Absolute Reduction in Stress Symptoms-9.5 ± 11.1-9.8 ± 11.9-4.1 ± 10.2
SecondaryMean Proportion of Days With MMT Adherence

Out of the first 183 days of study participation, the total number of days a participant attended their MMT visit appointment divided by 183 days.

Time frame:
Study baseline through 6 months of follow-up
Reported as:
Mean · proportion of days
Mean Proportion of Days With MMT Adherence
proportion of daysFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Mean Proportion of Days With MMT Adherence0.99 ± 0.030.99 ± 0.010.96 ± 0.14

Adverse events

Collected over Adverse events were collected from the time of signing informed consent through completion of the follow up period, a total of 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Friendship Bench Delivered by Professional Counselor0/26 (0%)1/26 (3.8%)2/26 (7.7%)
Friendship Bench Delivered by Lay Counselor1/25 (4%)0/25 (0%)1/25 (4%)
Enhanced Usual Care0/26 (0%)0/26 (0%)0/26 (0%)
Most frequent serious events
Most frequent serious events
EventFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
PancreatitisHepatobiliary disorders1/260/250/26
Most frequent other events
Most frequent other events
EventFriendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual Care
Suicidal Thoughts / IdeationsPsychiatric disorders2/261/250/26

Baseline characteristics

Two of the randomized participants (1-Friendship Bench Delivered by Professional Counselor and 1-Enhanced Usual Care) were found to be ineligible for the study shortly after enrollment and were excluded from all analyses.

Age, Continuous
Age, Continuous(years)Friendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual CareTotal
Mean44.1 ± 5.044.9 ± 7.244.9 ± 5.244.6 ± 5.8
Sex: Female, Male
Sex: Female, Male(Participants)Friendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual CareTotal
Female0112
Male25242473
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Friendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual CareTotal
Count of participants———0
Region of Enrollment
Region of Enrollment(Participants)Friendship Bench Delivered by Professional CounselorFriendship Bench Delivered by Lay CounselorEnhanced Usual CareTotal
Vietnam25252575
07

Study locations

1 site
  • CDC Hanoi
    Hanoi, Hanoi City, Vietnam
08

References and documents

Publications

  • Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005 Jun;44(Pt 2):227-39. doi: 10.1348/014466505X29657. PubMed 16004657 ↗
  • Le MTH, Tran TD, Holton S, Nguyen HT, Wolfe R, Fisher J. Reliability, convergent validity and factor structure of the DASS-21 in a sample of Vietnamese adolescents. PLoS One. 2017 Jul 19;12(7):e0180557. doi: 10.1371/journal.pone.0180557. eCollection 2017. PubMed 28723909 ↗
  • Tran TD, Tran T, Fisher J. Validation of the depression anxiety stress scales (DASS) 21 as a screening instrument for depression and anxiety in a rural community-based cohort of northern Vietnamese women. BMC Psychiatry. 2013 Jan 12;13:24. doi: 10.1186/1471-244X-13-24. PubMed 23311374 ↗
  • Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP; 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008 Nov 15;372(9651):1733-45. doi: 10.1016/S0140-6736(08)61311-2. Epub 2008 Sep 23. PubMed 18817968 ↗
  • Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23. Erratum In: Lancet Glob Health. 2018 Jan;6(1):e36. doi: 10.1016/S2214-109X(17)30446-1. PubMed 29074409 ↗
  • Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000 Jun;30 Suppl 2:S171-6. doi: 10.1086/313849. PubMed 10860902 ↗
  • Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008 Aug;103(8):1242-57. doi: 10.1111/j.1360-0443.2008.02269.x. PubMed 18855813 ↗
  • Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):567-8. doi: 10.1001/jama.280.6.567. No abstract available. PubMed 9707152 ↗
  • Jordan MR, Obeng-Aduasare Y, Sheehan H, Hong SY, Terrin N, Duong DV, Trung NV, Wanke C, Kinh NV, Tang AM. Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS. 2014 Aug;25(9):662-668. doi: 10.1177/0956462413516301. Epub 2013 Dec 18. PubMed 24352130 ↗
  • Mathers BM, Degenhardt L, Bucello C, Lemon J, Wiessing L, Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ. 2013 Feb 1;91(2):102-23. doi: 10.2471/BLT.12.108282. PubMed 23554523 ↗
  • Weber R, Huber M, Battegay M, Stahelin C, Castro Batanjer E, Calmy A, Bregenzer A, Bernasconi E, Schoeni-Affolter F, Ledergerber B; Swiss HIV Cohort Study. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV Med. 2015 Mar;16(3):137-51. doi: 10.1111/hiv.12184. Epub 2014 Aug 15. PubMed 25124393 ↗
  • Lappalainen L, Hayashi K, Dong H, Milloy MJ, Kerr T, Wood E. Ongoing impact of HIV infection on mortality among people who inject drugs despite free antiretroviral therapy. Addiction. 2015 Jan;110(1):111-9. doi: 10.1111/add.12736. Epub 2014 Oct 16. PubMed 25203392 ↗
  • Adams C, Zacharia S, Masters L, Coffey C, Catalan P. Mental health problems in people living with HIV: changes in the last two decades: the London experience 1990-2014. AIDS Care. 2016;28 Suppl 1(sup1):56-9. doi: 10.1080/09540121.2016.1146211. Epub 2016 Feb 17. PubMed 26888472 ↗
  • Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008 May;70(4):505-11. doi: 10.1097/PSY.0b013e31816aa0cc. Epub 2008 Mar 31. PubMed 18378865 ↗
  • Bouhnik AD, Preau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10(1):53-61. PubMed 15751763 ↗
  • Jones DL, Waldrop-Valverde D, Gonzalez P, Mack A, Kumar AM, Ownby R, Weiss SM, Kumar M. Mental health in HIV seronegative and seropositive IDUs in South Florida. AIDS Care. 2010 Feb;22(2):152-8. doi: 10.1080/09540120903039851. PubMed 19662550 ↗
  • Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care. 2009 Aug;21(8):976-83. doi: 10.1080/09540120802657555. PubMed 20024753 ↗
  • WHO Secretariat. HIV/AIDS and mental health. World Health Institution; 2008.
  • Tran HV, Nong HTT, Tran TTT, Filipowicz TR, Landrum KR, Pence BW, Le GM, Nguyen MX, Chibanda D, Verhey R, Go VF, Ho HT, Gaynes BN. Adaptation of a Problem-solving Program (Friendship Bench) to Treat Common Mental Disorders Among People Living With HIV and AIDS and on Methadone Maintenance Treatment in Vietnam: Formative Study. JMIR Form Res. 2022 Jul 8;6(7):e37211. doi: 10.2196/37211. PubMed 35802402 ↗

Study documents

  • Protocol and statistical analysis plan · Oct 1, 2023
  • Informed consent form · Apr 1, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).

09

Registry details

Key details

Study ID
NCT04790201
Lead sponsor
University of North Carolina, Chapel Hill
Collaborators
Hanoi Medical University, The Friendship Bench Trust, National Institute on Drug Abuse (NIDA)
Responsible party
Sponsor
First posted
Mar 10, 2021
Start date
Feb 28, 2022
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Results posted
Aug 13, 2024
Last update
Aug 13, 2024

Study contacts

Bradley Gaynes, MD, MPH
principal investigator · University of North Carolina, Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion